Abstract:Most commonly used intercalating fluorescent dyes in DNA detection are lacking any sequence specificity, whereas so‐called Exciton Primers can overcome this limitation by functioning as “sequence‐specific dyes.” After hybridization to complementary sequences, the fluorescence of Exciton Primers provides sequence‐specific signals for real‐time monitoring of amplification reactions. Applied to the SmartAmp2 mutation detection process, Exciton Primers show high signal strength with low background leading to a sup… Show more
“…We have reported fluorescent oligonucleotide probes labeled with a TO dimer unit, which we call ECHO (exciton-controlled hybridization-sensitive fluorescent oligonucleotide) probes, for the detection of single-stranded DNA and RNA. [21][22][23][24][25][26][27][28][29][30][31][32] ECHO probes emitting low background fluorescence were expected to be also applicable to detect double-stranded DNA as TO molecules emit intense fluorescence in the presence of DNA triplexes. 15,17 However, DNA triplexes formed by ECHO probes have not been reported and the photophysical properties are unknown.…”
“…We have reported fluorescent oligonucleotide probes labeled with a TO dimer unit, which we call ECHO (exciton-controlled hybridization-sensitive fluorescent oligonucleotide) probes, for the detection of single-stranded DNA and RNA. [21][22][23][24][25][26][27][28][29][30][31][32] ECHO probes emitting low background fluorescence were expected to be also applicable to detect double-stranded DNA as TO molecules emit intense fluorescence in the presence of DNA triplexes. 15,17 However, DNA triplexes formed by ECHO probes have not been reported and the photophysical properties are unknown.…”
“…Another advantage of the SmartAmp-2 assay is that the reaction proceeds in an isothermal condition and only simple equipment is needed to maintain the appropriate temperature. The method can be improved further with fluorescence-labeled oligonucleotides called "exciton primers," where visible fluorescent signals are emitted using UV or regular halogen lamps (14). These inventions will allow medical personnel to determine these genotypes even at the bedside in the near future.…”
Abstract. Organic anion-transporting polypeptide (OATP) 1B1, encoded by the solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene, mediates the active uptake of various organic anions into hepatocytes and determines their hepatic clearances as the first step in the detoxification pathway. Previous reports indicated that alterations in its function by drug-drug interactions or genetic polymorphisms affect the pharmacokinetics of the substrate drugs. In the present study, we developed a method to genotype SLCO1B1 388A>G (rs2306283) and 521>C (rs4149056), which significantly affect the clinical pharmacokinetics and subsequent side effects such as myopathy caused by statins, OATP1B1 substrates in humans. We used a small aliquot of blood and the isothermal Smart Amplification Process version 2 (SmartAmp-2), which could complete the genotyping of 388A>G and 521T>C within 60 min. The genotypes of 101 genomic DNA samples and blood samples assessed by SmartAmp-2 matched perfectly to those determined previously by the conventional PCR-SSCP method. The SmartAmp-2 method enables the rapid identification of the 388A>G and 521T>C genotypes, saving time and effort in the genomic DNA preparation in clinical practice. This method will be useful for evaluating and predicting altered pharmacological and toxicological effects of substrate drugs caused by SLCO1B1 polymorphisms.
“…POC Genotype technologies continue to advance and molecular biology methodologies, such as SmartAmp 2 [37] are reducing the time to obtain a genotype further. It is already possible to determine genotypes for pharmacogenomics-related variants such as those associated with warfarin dose requirement ( VKORC1 and CYP2C9 ) in 30–40 min [37,38].…”
The completion of the human genome project 10 years ago was met with great optimism for improving drug therapy through personalized medicine approaches, with the anticipation that an era of genotype-guided patient prescribing was imminent. To some extent this has come to pass and a number of key pharmacogenomics markers of inter-individual drug response, for both safety and efficacy, have been identified and subsequently been adopted in clinical practice as pre-treatment genetic tests. However, the universal application of genetics in treatment guidance is still a long way off. This review will highlight important pharmacogenomic discoveries which have been facilitated by the human genome project and other milestone projects such as the International HapMap and 1000 genomes, and by the continued development of genotyping and sequencing technologies, including rapid point of care pre-treatment genetic testing. However, there are still many challenges to implementation for the many other reported biomarkers which continue to languish within the discovery phase. As technology advances over the next 10 years, and the costs fall, the field will see larger genetic data sets, including affordable whole genome sequences, which will, it is hoped, improve patient outcomes through better diagnostic, prognostic and predictive biomarkers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.